Brief: United Therapeutics Corporation Announces Full Enrollment Of The Teton 2 Study Of Inhaled Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis
10/07/2024 12:13
July 10 (Reuters) - United Therapeutics Corp UTHR.O :
* UNITED THERAPEUTICS CORPORATION ANNOUNCES FULL ENROLLMENT
OF THE
TETON 2 STUDY OF INHALED TREPROSTINIL FOR THE TREATMENT OF
IDIOPATHIC PULMONARY FIBROSIS
* UNITED THERAPEUTICS CORP - TOP LINE DATA EXPECTED IN
SECOND HALF
OF 2025
Source text for Eikon: ID:nBw5hx6Pda
Further company coverage: UTHR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug